Portfolio company
Wobble Genomics
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
This company develops full-length RNA sequencing technology for pharmaceutical and diagnostic organisations to improve biomarker discovery, patient stratification and clinical success rates.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
BioSkryb
This company develops genomic amplification and sequencing systems for researchers and clinicians to analyse DNA and RNA from single cells.
Lucid Genomics
This company develops an artificial intelligence platform for long-read genomic data interpretation to assist clinical laboratories and pharmaceutical researchers with diagnostics.
Single Cell Discoveries
This company provides single-cell sequencing and spatial transcriptomics services to pharmaceutical, biotechnology and academic organisations to support drug discovery and biological research.
ArgenTAG
This company develops single-cell genomic sequencing kits and barcoding technology for researchers to analyse complex biological data using long-read sequencing platforms.
QuirieGen
This company develops single-cell multi-omic technologies and AI models for drug discovery and development within the pharmaceutical sector.
Genetic Sequencing
This company develops nanopore-based technology for DNA sequencing to support researchers and clinicians in medical diagnostics and genomic analysis.
3X Genetics
This company develops long-read genetic testing technology and diagnostics for biopharma companies to identify patients with rare repeat expansion disorders.
CS Genetics
This company develops instrument-free single-cell genomics kits for academic researchers and biopharmaceutical organisations to perform transcriptomics without expensive hardware.
